P094 Effectiveness and security of secukinumab in patients with psoriastic arthritis in real clinical practice
Authors: R Hernández, J Uceda, A Perez Gil, JL Marenco
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Career situation of first and presenting author</h3> Student for a master or a PhD. <h3>Introduction</h3> Recently new therapeutic targets have been approved for the treatment of psoriatic arthritis (PSA). We have limited experience in real clinical practice. <h3>Objectives</h3> To assess efficacy, safety and tolerability of secukinumab in patients with active PsA. <h3>Methods</h3> Descriptive, retrospective observational study on the efficacy and safety of secukinumab in patients who met CASPAR clasification criteria for PsA in follow-up in the Virgen de Valme hospital area. We evaluate, measures of disease activity by DAPSA in peripheral forms and ASDAS in axial forms. <h3>Statistical analysis</h3> The quantitative variables are expressed with means and standard deviations or medians and quartiles if the distributions are asymmetric, and the qualitative variables with percentages. <h3>Results</h3> 12 patients were reviewed. 58.3% were male.The average age of these patients is 47.67 years.The mean time of evolution in years of the disease was 8.33. 75% of the sample was not a smoker, and 83.3% of patients didn´t consume alcohol excessively. 25% were hypertensive. 8.3% had an associated dyslipidemia, and 16.7% had a symptomatic hyperuricemia. Oligoarthritis form was the most frequent patterns of presentation with 46%, followed by polyarthritis with 27%. All patients had previously failed at least one DMARD, the most frequent being Methotrexate (41.7%), Up to 75% of the patients were naïve to biological therapy. In patients refractory to biological therapy, the most commonly used drug in first choice was etanercept. In peripheral presentation 80% of the patients had a moderate DAPSA at the beginning of the treatment and of these 62% passed to a low activity, while 38% they remained with moderate activity. In patients with high activity, up to 70% went to a low activity DAPSA, and in 30% it decreased to moderate activity. We have survival with the drug that has been 12.67 months with a DS of 7.07 months. Treatment has been suspended in 3 patients, in one of them due to severe skin and joint breakout, in another due to nausea and headaches, and the last due to ineffectiveness. Finally, regarding the safety data we have not had any severe adverse effects. 8.3% had mild adverse effects, the most frequent being infectious symptoms of the upper respiratory tract. 8.3% had a primary failure (no response at any time) compared to 25% that has presented a secondary failure after a good initial response to treatment. <h3>Conclusions</h3> Secukinumab provided sustained improvements in signs and symptoms in patients of active and was well tolerated, with a safety profile consistent with that reported previously. <h3>Reference</h3> McInnes IB, Mease PJ, <i>et al</i>. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): Future 2 Study Group. <i>Lancet</i> 386(9999):1137–46. <h3>Disclosure of Interest</h3> None declared.